A new book from Halee Fischer-Wright, MD, CEO of MGMA, examines how we need to strike a balance between the three major elements of medicine.
In this interview we discuss the ASCO provisional clinical opinion on second-line hormonal therapy for chemotherapy-naive castration-resistant prostate cancer.
In this interview we discuss the phase III trial of aldoxorubicin in patients with advanced soft-tissue sarcoma, which showed improved efficacy and reduced toxicity over doxorubicin.
An independent physician and a health IT executive join the podcast to talk about the current landscape of technology in medicine.
Dr. Robert Wachter wrote the book on the failings of health IT and the effect these systems have on patient safety. He joined us for the Pearls podcast.
In this interview we discuss new data on the use of radiotherapy in cancer patients with brain metastases.
In this interview we discuss the effect of the gut microbiome on responses and survival outcomes in metastatic melanoma patients treated with anti–PD-1 immunotherapies.
Dr. Karen Reckamp talks about ways to incorporate biomarkers for the treatment of lung cancer with immunotherapy into clinical practice at the 2017 American Society of Clinical Oncology Annual Meeting, held June 2–6 in Chicago.
In this interview we discuss how relapse in multiple myeloma manifests and treatment options for relapsed/refractory patients.
The telemedicine phenomenon is growing, especially in pediatrics. This podcast looks at why the specialty is an ideal landing spot for the technology.